Clinical trial
HCV-796 and Midazolam Drug Interaction Study in Healthy Subjects
NCT00410254 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00410254 |
|---|---|
| Title | HCV-796 and Midazolam Drug Interaction Study in Healthy Subjects |
| Official title | An Open Label, Single-Dose Midazolam, Multiple-Dose HCV-796, Sequential 3-Period Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Midazolam |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | HCV-796, midazolam |
| Enrollment | 38 |
| Start date | Jun 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Dec 12, 2006 |
| Last update posted | Dec 5, 2007 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: